Porton Advanced Solutions completes a Series B financing round to expand its end-to-end Gene and Cell Therapy CDMO Platforms
Retrieved on:
Monday, August 22, 2022
Momentum, Science and technology in Asia, CEO, Technology, Program, Research, Agriculture, View, Suzhou Industrial Park, Virus, TMT, LTD, Health, Science, CDMO, GMP, Medicine, Compliance, Plasmid, IP, AD, China Merchants Group, RNA transfection, CSC, Patient, Information, Parallel (filling stations operator), CMC, CGMP, GCT, Industry, AAV, Mining, Trust, Investment, EQUITY, AUM, IIT, Multimedia, API, Growth, Drug development, Empowerment, Transport, IND, HM Capital Partners, RMB, PD, Therapy, Record, Bank, Fine chemical, Pharmaceutical industry, Financial services, EU, Fosun International
SUZHOU, China, Aug. 21, 2022 /PRNewswire/ -- On August 19, 2022, Porton Advanced Solutions (Porton Advanced) announced the completion of its Series B financing round with over US$80Million.
Key Points:
- SUZHOU, China, Aug. 21, 2022 /PRNewswire/ -- On August 19, 2022, Porton Advanced Solutions (Porton Advanced) announced the completion of its Series B financing round with over US$80Million.
- Focusing solely on gene and cell therapy CDMO services, Porton Advanced has rapidly established an integrated CDMO platform providing a spectrum of services covering plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy and microbial vectors used for gene therapy (MVGTs).
- By then, Porton Advanced will have over 200,000sqft of PD, AD, and GMP manufacturing facility dedicated for gene and cell therapy.
- Porton Advanced is a leading cell and gene therapy CDMO service provider with a very experienced, internationally oriented management and technical team.